A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)-Reference-Cited by-同舟云学术

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

Published:2022-12 Issue:6 Volume:7 Page:100601
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Schmidt M.,Lübbe K.,Decker T.,Thill M.,Bauer L.,Müller V.,Link T.,Furlanetto J.,Reinisch M.,Mundhenke C.,Hoffmann O.,Zahn M.-O.,Müller L.,Denkert C.,van Mackelenbergh M.,Fasching P.A.,Burchardi N.,Nekljudova V.,Loibl S.

Funder

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5);Cardoso;Ann Oncol,2020

2. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline;Rugo;J Clin Oncol,2016

3. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021;Thill;Breast Care (Basel),2021

4. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies;Murphy;Endocr Relat Cancer,2016

5. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects;Miricescu;Int J Mol Sci,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study;ESMO Open;2024-09

2. The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features;The Journal of Pathology: Clinical Research;2024-04-02

3. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis;Journal of Gastrointestinal Oncology;2024-04

4. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer;The Lancet Oncology;2024-04

5. A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer;Anticancer Research;2024-03-27